Key result
Replacing traditional vendor QTc alerts with a custom QTc risk alert did not reduce the occurrence of QTc prolongation in hospitalized patients.
Why the study?
The study evaluated replacing medication knowledge vendor alerts with a customized EHR QTc risk alert strategy to minimize QTc prolongation, minimize exposure to QTc-prolonging medications, and decrease overall alerts in hospitalized patients.
Does a custom QTc risk alert based on a validated scoring tool reduce QTc prolongation and exposure to QTc prolonging medications in adult inpatients compared to traditional vendor-based alerts?
Observational (n=3,691)
Unblinded
No
Does a custom QTc risk alert based on a validated scoring tool reduce QTc prolongation and exposure to QTc prolonging medications in adult inpatients compared to traditional vendor-based alerts?
Answers are grounded in this paper and cite their sources.
Replacing traditional vendor-based QTc alerts with a customized risk-based alert significantly reduced orders for QTc-prolonging medications and improved alert action rates without increasing QTc prolongation.
Objective The aim of the study is to implement a customized QTc interval clinical decision support (CDS) alert strategy in our electronic health record for hospitalized patients and aimed at providers with the following objectives: minimize QTc prolongation, minimize exposure to QTc prolonging medications, and decrease overall QTc-related alerts. A strategy that was based on the validated QTc risk scoring tool and replacing medication knowledge vendor alerts with custom QTc prolongation alerts was implemented. Methods This is a retrospective quasi-experimental study with a pre-intervention period (August 2019 to October 2019) and post-intervention period (December 2019 to February 2020). The custom alert was implemented in November 2019. Results In the pre-implementation group, 361 (19.3%) patients developed QTc prolongation, and in the post-implementation group, 357 (19.6%) patients developed QTc prolongation (OR: 1.02, 95% CI: 0.87–1.20, p = 0.81). The odds ratio of an action taken post-implementation compared with pre-implementation was 18.90 (95% CI: 14.03–25.47, p <0. 001). There was also a decrease in total orders for QTc prolonging medications from 7,921 (5.5%) to 7,566 (5.3%) with an odds ratio of 0.96 (95% CI: 0.93–0.99, p = 0.01). Conclusion We were able to decrease patient exposure to QTc prolonging medications while not increasing the rate of QTc prolongation as well as improving alert action rate. Additionally, there was a decrease in QTc prolonging medication orders which illustrates the benefit of using a validated risk score with a customized CDS approach compared with a traditional vendor-based strategy. Further research is needed to confirm if an approach implemented at our organization can reduce QTc prolongation rates.
No takes yet. Share an insight, caveat, or question.
Stettner et al. (2022) conducted an observational in Hospitalized patients at risk for QTc prolongation (n=3,691). Custom QTc risk alert vs. Traditional vendor-based QTc alerts was evaluated on Occurrence of QTc prolongation (OR 1.02, 95% CI 0.87-1.20, p=0.81). Replacing traditional vendor QTc alerts with a custom QTc risk alert did not reduce the occurrence of QTc prolongation in hospitalized patients.
Synapse has enriched 10 related papers. Consider them for comparative context: